Diagnostic Enterovirus 71 (VP1) antibodies (anti-Enterovirus 71, anti-VP1) and antigens (recombinant Enterovirus 71 (VP1) protein) for Infectious disease VP1 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Cat:GMP-IVD-P041-Tg001
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Infectious disease (neurological diseases ) and related syndrome. GeneMedi offers paired diagnostics grade Enterovirus 71 (VP1) antibodies (monoclonal antibody, mab) and antigens for Infectious disease (neurological diseases ) rapid test kit of Enterovirus 71 (VP1) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Infectious disease (neurological diseases ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.
Genemedi produces core diagnostic ingredients for test of Infectious disease (neurological diseases ) and related syndrome. GeneMedi offers paired diagnostics grade Enterovirus 71 (VP1) antibodies (monoclonal antibody, mab) and antigens for Infectious disease (neurological diseases ) rapid test kit of Enterovirus 71 (VP1) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Infectious disease (neurological diseases ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Enterovirus 71 (EV71), the newest member of Enterovirudae, is notable for its etiological role in epidemics of severe neurological diseases in children. It appears to be emerging as an important virulent neurotropic enterovirus in the upcoming era of poliomyelitis eradication. The illness usually peaks in June or July. EV71 infection may be asymptomatic or may cause diarrhea and rashes. EV71 one of the major causative agents for hand, foot and mouth disease (HFMD), is sometimes associated with severe central nervous system diseases. Direct detection of virus is the mainstay of diagnosis. EV71 can be isolated from throat and stool specimens, as well as from skin vesicle fluid. PCR testing provides generally greater sensitivity than culture for throat and stool specimens, and viral RNA has also been detected in vesicular fluid, blood and urine. EV71 specifc serological assays, including tests specific for IgM antibody, have also been developed to assist for early and easier diagnosis of the disease
Product Description
Cat No. of Pruducts
GMP-IVD-P041-Tg001-Ag01
Product Name
Recombinant human Enterovirus 71 (EV71) VP1 Protein
Target
Enterovirus 71
Alias of Target/Biomarker
Expression platform
E.coli
Isotypes
Recombinant Antigen
Bioactivity validation
Enterovirus 71 (VP1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in VP1 level test of Infectious disease (neurological diseases ) and related syndrome evaluation
Tag
His
Products description
Recombinant human Enterovirus 71 (EV71) VP1 Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Enterovirus 71 (EV71)
Purity
Purity: ≥95% (SDS-PAGE)
Application
Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -82℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous slide
Next slide
Cat No. of Pruducts
GMP-IVD-P041-Tg001-Ab01,GMP-IVD-P041-Tg001-Ab02
Product Name
Anti-human Enterovirus 71 (EV71) VP1 mouse monoclonal antibody (mAb)
Target
Enterovirus 71
Alias of Target/Biomarker
#N/A
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Enterovirus 71 (EV71) Enterovirus 71 (VP1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Enterovirus 71 (VP1) antibodies in VP1 level test of Infectious disease (neurological diseases ) and related syndrome evaluation.
Tag
mFc
Products description
Anti-human Enterovirus 71 (EV71) VP1 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Enterovirus 71 (VP1) antibodies.
Reconized/Reactive Species
Enterovirus 71 (EV71)
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -83℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
